As of Jun 30, 2025, the HAE stock has a PE ratio of 22.41. The calculation is based on the latest EPS of $3.33 and the stock price of $74.61 per share. A decrease of 25% has been observed in the PE ratio compared to its average of 29.7 of the last four quarters.
The mean historical PE ratio of Haemonetics over the last ten years is 104.97. The current 22.41 P/E ratio is 79% lower than the historical average. Looking back at the last ten years, HAE's PE ratio peaked in the Sep 2017 quarter at 641, with a price of $44.87 and an EPS of $0.07. The Mar 2025 quarter marked the lowest point at 18.98, with a price of $63.19 and an EPS of $3.33.
Maximum annual increase: 183.71% in 2015
Maximum annual decrease: -51.48% in 2023
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2025 | 18.98 | -48.41% | $63.19 | $3.33 |
2024 | 36.79 | 0.93% | $85.35 | $2.32 |
2023 | 36.45 | -51.48% | $82.75 | $2.27 |
2022 | 75.12 | 5.27% | $63.85 | $0.85 |
2021 | 71.36 | 6.75% | $112.04 | $1.57 |
2020 | 66.85 | -18.24% | $100.95 | $1.51 |
2019 | 81.76 | -3.89% | $87.48 | $1.07 |
2018 | 85.07 | N/A | $73.16 | $0.86 |
2017 | N/A | N/A | $40.57 | -$0.51 |
2016 | N/A | N/A | $35.29 | -$1.09 |
2015 | 133.97 | 183.71% | $44.21 | $0.33 |
2014 | 47.22 | -13.86% | $32.11 | $0.68 |
2013 | 54.82 | 107.73% | $41.66 | $0.76 |
2012 | 26.39 | 26.09% | $34.84 | $1.32 |
2011 | 20.93 | -14.78% | $33.29 | $1.59 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 18.98 | -37.36% | $63.19 | $3.33 |
Dec 2024 | 30.3 | -7.73% | $77.57 | $2.56 |
Sep 2024 | 32.84 | -10.3% | $79.8 | $2.43 |
Jun 2024 | 36.61 | -0.49% | $82.73 | $2.26 |
Mar 2024 | 36.79 | 7.57% | $85.35 | $2.32 |
Dec 2023 | 34.2 | -3.42% | $85.51 | $2.5 |
Sep 2023 | 35.41 | 11.88% | $89.58 | $2.53 |
Jul 2023 | 31.65 | -13.17% | $85.14 | $2.69 |
Apr 2023 | 36.45 | -12.88% | $82.75 | $2.27 |
Dec 2022 | 41.84 | -5.06% | $78.65 | $1.88 |
Oct 2022 | 44.07 | -13.59% | $74.03 | $1.68 |
Jul 2022 | 51 | -32.11% | $67.32 | $1.32 |
Apr 2022 | 75.12 | -39.1% | $63.85 | $0.85 |
Jan 2022 | 123.35 | 4.51% | $53.04 | $0.43 |
Oct 2021 | 118.03 | 125.08% | $72 | $0.61 |
The current PE ratio of HAE is lower than its 3, 5 and 10-year averages.
In comparison to its peers TMO and SYK, HAE's PE ratio is lower, but it is higher than JNJ's. Haemonetics's PE ratio is trading below the peer average of 30.12.
Stock name | PE ratio | Market cap |
---|---|---|
JNJ Johnson & Johnson | 17.14 | $373.69B |
HAE Haemonetics Corp | 22.89 | $3.66B |
MDT Medtronic plc | 24.3 | $113.02B |
TMO Thermo Fisher Scientific Inc | 24.63 | $158.92B |
BDX Becton Dickinson & Co | 34.05 | $50.56B |
SYK Stryker Corp | 52.86 | $151.5B |
CERS Cerus Corp | N/A | $279.09M |
BAX Baxter International Inc | N/A | $15.92B |
As of Jun 30, 2025, HAE stock has a price to earnings ratio of 22.41.
The 3-year average price to earnings ratio for HAE stock is 35.85.
The 5-year average price to earnings ratio for HAE stock is 50.92.
Over the last ten years, the quarterly PE ratio reached its highest level at 641 in the Sep 2017 quarter.
HAE's current price to earnings ratio is 79% below its 10-year historical average.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Jun 30, 2025), Haemonetics's share price is $74.61. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $3.33. Therefore, Haemonetics's PE ratio for today is 22.41. PE RATIO(22.41) = STOCK PRICE($74.61) / TTM EPS($3.33)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.